Target intelligence / Profile preview

DNA damage process

Molecular classification
Other (not a single molecule, receptor, enzyme, or protein family), Biological pathway/process
01

Overview

The "DNA damage process" refers broadly to the collection of events by which cells recognize and respond to various forms of injury inflicted upon their genetic material. This includes detection mechanisms that sense damaged bases or strand breaks; signaling cascades that halt cell division; recruitment and activation of specialized proteins responsible for excision, reversal, or bypassing lesions; and ultimate decisions between successful restoration versus programmed cell death if errors are irreparable. The main types include direct reversal mechanisms, base excision repair, nucleotide excision repair, mismatch correction systems, non-homologous end joining (NHEJ), homologous recombination (HR), among others[1][2][3]. While individual proteins within these pathways are valid therapeutic targets—especially in oncology—the overall "process" is not considered a discrete molecular entity suitable for targeted drug development.

Other names
DNA damage responseDNA repair processGenomic integrity maintenanceCellular response to DNA damage
02

Mechanism of action

Drugs targeting this area generally: - Inhibit specific enzymes required for DNA repair, leading to accumulation of lethal lesions. - Induce excessive DNA damage beyond the capacity for cellular repair, triggering apoptosis.

03

Biological functions

Maintenance of genome stabilityCell cycle regulation and arrestActivation of apoptosis (programmed cell death)Induction of cellular senescenceSignal transduction for repair pathways
04

Disease associations

Cancer (defects in the process increase cancer risk)Neurodegenerative disease (impaired repair contributes to pathology)Aging-related diseases (accumulation of unrepaired damage)
05

Safety considerations

Off-target toxicity due to effects on normal cells’ genomic integrityIncreased risk of secondary malignancies from mutagenesisBone marrow suppression and immunosuppression due to high turnover tissues being affected by impaired repair
06

Interacting drugs

PARP inhibitors (e.g., olaparib)

3 more in the full profile.

07

Biomarkers

γ-H2AX foci (as indirect measures of double-strand breaks)Deficiency or mutation status in key genes like BRCA1/2 (for therapy selection)

Beyond the preview

Go deeper on DNA damage process.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA damage process.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call